A collaboration to enhance the delivery of biotherapeutics and generate transformative therapies for patients

Crystec Ltd. and Biosidus S.A. are delighted to announce their collaboration focused on enhancing the delivery and performance of biotherapeutics. The overarching aim of the non-exclusive partnership is to apply Crystec’s proprietary mSAS® (modified supercritical antisolvent) supercritical fluid particle engineering platform to selected Biosidus products in order to generate a range of innovative, differentiated medicines. The first programme prioritised in the cooperation aims to accelerate the development of a dry powder preparation of teriparatide for the treatment of osteoporosis.

Teriparatide is a powerful anabolic treatment (a parathyroid hormone analog) which is used in the management of glucocorticoid-induced osteoporosis and fractures in patients with very low bone density. It is typically administered by daily injections over the course of a 2-year period. Crystec and Biosidus are working together with the ambition of eliminating the need for daily injections, by means of enabling administration via more patient friendly routes, such as through the lungs or via the nose. As such, the programme aims to apply mSAS® to develop dry, free flowing teriparatide powders with high levels of retained biological activity, a targeted particle size and optimal aerodynamic performance for effective delivery to the lung or nasal cavity, ultimately enabling rapid systemic uptake.

Marcelo Criscuolo, Scientific Director at Biosidus, said: “We are passionate about making our vital therapies accessible and convenient for those who require them. Our ultimate ambition is to eliminate the need for daily injections meaning that men, women and children who suffer from long term and chronic illnesses are not subjected to additional discomfort in the course of their treatment. Working with Crystec’s innovative mSAS® technology opens up the possibility of maximising the therapeutic potential of these drugs through retaining improved biological activity levels and enabling ‘needle free’ delivery options for our patients”.

Commenting from Crystec, Paul Thorning, CEO, said: “We are delighted to work with Biosidus in this important area of drug delivery. Our collaboration provides significant potential to demonstrate the power of the mSAS® platform in simplifying biopharmaceutical processing, whilst facilitating the accelerated development of inhaled and nasal products that could be truly transformative for patients.”

About Biosidus S.A. 

Biosidus is an Argentina-based company with an impressive track record in the development, manufacture and supply of top quality biosimilars commercially available across four continents through a vast network of licensees.

Currently its R&D activities are focused on accelerating market entry of a robust pipeline of biosimilars and on other innovative technologies such as Gene Therapy applied to the management of central and peripheral vascular disease.

About Crystec Ltd.

Crystec is a UK-based crystal and particle engineering company, applying proprietary ‘mSAS®’ (modified Supercritical Anti-Solvent) drug delivery technology to improve the performance of medicines. Crystec’s technology enables drug molecules to be crystallized in new forms and novel particles to be manufactured in ways that can greatly enhance their clinical effect. The mSAS® process is highly efficient, stable, fully scalable and is approved by regulatory authorities. Crystec works with the global pharmaceutical and health care industry to solve drug particle formation, formulation and process challenges. The company is also developing innovative therapies in important areas of unmet clinical need, including women’s health, urology and respiratory disease.